AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9627287 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingectomy followed by IVF with combined GnRH agonist and hMG therapy
Number of subjects: 60
Study 7947102 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and interferon alpha (5-FU/IFN-alpha)
Number of subjects: 24
Study 7947102 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil and leucovorin (5-FU/L-leucovorin)
Number of subjects: 24
Study 3311552 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (100 gm/70 kg protein/day)
Number of subjects: 5
Study 3311552 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted diet (19 gm/70 kg protein/day)
Number of subjects: 5
Study 31928931 — intervention group
Group type: COMPARATOR
Intervention: Multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors
Number of subjects: 0
Study 30664114 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive static stretching for 120 seconds
Number of subjects: 13
Study 30664114 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive static stretching for 30 seconds
Number of subjects: 13
Study 30664114 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive static stretching for 60 seconds
Number of subjects: 13
Study 30664114 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 13
Study 28505470 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted food response and attention training with personalized high- and low-calorie food images
Number of subjects: 0
Study 28505470 — intervention group
Group type: COMPARATOR
Intervention: Control training with non-food images
Number of subjects: 0
Study 25163656 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (lower two-thirds of the rectum)
Number of subjects: 725
Study 25163656 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (upper third of the rectum and rectosigmoid junction)
Number of subjects: 725
Study 25163656 — intervention group
Group type: COMPARATOR
Intervention: Group C (colon)
Number of subjects: 725
Study 25163656 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Group A to Group C
Number of subjects: 725
Study 25163656 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Group B to Group C
Number of subjects: 725
Study 23356656 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative message (stress causes ill health)
Number of subjects: 0
Study 23356656 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-normative message (stress provides challenge, growth, and development)
Number of subjects: 0
Study 23356656 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21734588 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (450 mg/day)
Number of subjects: 153
Study 21734588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 19498345 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (approximately 1,000 fewer calories per day for 9 weeks)
Number of subjects: 60
Study 19498345 — intervention group
Group type: COMPARATOR
Intervention: Control group (weight stability maintained for 4 weeks after randomization)
Number of subjects: 60
Study 17106345 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up intervention by specially trained nurses over 1 year
Number of subjects: 343
Study 17106345 — intervention group
Group type: COMPARATOR
Intervention: Control group received written information only
Number of subjects: 343
Study 15557371 — intervention group
Group type: COMPARATOR
Intervention: On-pump surgery (n=192)
Number of subjects: 400
Study 15557371 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery (n=208)
Number of subjects: 400
Study 15557371 — intervention group
Group type: EXPERIMENTAL
Intervention: Other arteries (off-pump)
Number of subjects: 400
Study 14656781 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.05 mg with tetracaine
Number of subjects: 42
Study 14656781 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.10 mg with tetracaine
Number of subjects: 42
Study 14656781 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine 10 mg alone
Number of subjects: 42
Study 11078064 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry of attic cholesteatomas
Number of subjects: 0
Study 11078064 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up studies on patients with attic retractions
Number of subjects: 0
Study 8962928 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 36
Study 8962928 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 36
Study 8962928 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 36
Study 1480451 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA patch
Number of subjects: 160
Study 1480451 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 160
Study 2933057 — intervention group
Group type: COMPARATOR
Intervention: Bladder catheterization
Number of subjects: 83
Study 2933057 — intervention group
Group type: EXPERIMENTAL
Intervention: No catheterization
Number of subjects: 83
Study 30099859 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a soft knee brace
Number of subjects: 44
Study 30099859 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 44
Study 30552275 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate containing 99% cocoa, 10g daily for 6 months
Number of subjects: 140
Study 30552275 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 140
Study 26222203 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic glucocorticosteroids
Number of subjects: 1
Study 25163019 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1 g twice daily
Number of subjects: 30
Study 25163019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22650270 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group (N = 15)
Number of subjects: 47
Study 22650270 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo group (N = 17)
Number of subjects: 47
Study 22650270 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 15)
Number of subjects: 47
Study 21086563 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotics system (ES)
Number of subjects: 71
Study 21086563 — intervention group
Group type: COMPARATOR
Intervention: Video-colonoscopy
Number of subjects: 71
Study 18322739 — intervention group
Group type: EXPERIMENTAL
Intervention: MIVAT
Number of subjects: 30
Study 18322739 — intervention group
Group type: COMPARATOR
Intervention: Conventional thyroidectomy
Number of subjects: 30
Study 16026368 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg/day
Number of subjects: 48
Study 16026368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12421835 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin A supplementation (60 mg retinol palmitate at 18-42 days postpartum)
Number of subjects: 0
Study 12421835 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant vitamin A supplementation (7.5 mg at 6, 10, and 14 weeks of age)
Number of subjects: 0
Study 12421835 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both mothers and infants)
Number of subjects: 0
Study 10592404 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS), given once daily for 1 week
Number of subjects: 5
Study 7475716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine
Number of subjects: 55
Study 7475716 — intervention group
Group type: COMPARATOR
Intervention: Control (Meningococcal vaccine)
Number of subjects: 55
Study 2206119 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric restrictive procedures
Number of subjects: 240
Study 6986945 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanozolol plus elastic stockings
Number of subjects: 23
Study 6986945 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus elastic stockings
Number of subjects: 23
Study 31724501 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine brush-on gel
Number of subjects: 30
Study 31724501 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study 28651681 — intervention group
Group type: COMPARATOR
Intervention: 0 mg of Ca (as calcium carbonate)
Number of subjects: 25
Study 28651681 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of Ca (as calcium carbonate)
Number of subjects: 25
Study 28651681 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of Ca (as calcium carbonate)
Number of subjects: 25
Study 25976603 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw thrust-assisted technique
Number of subjects: 42
Study 25976603 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (anterior jaw lift technique)
Number of subjects: 42
Study 25976603 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 23952776 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching methodologies (specific methodologies not detailed)
Number of subjects: 0
Study 21576473 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP-containing treatment arm
Number of subjects: 232
Study 21576473 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir-containing treatment arm
Number of subjects: 232
Study 20179410 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 0
Study 20179410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 0
Study 20179410 — intervention group
Group type: COMPARATOR
Intervention: Control (non-psychiatric)
Number of subjects: 0
Study 16736729 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalpha‐methylhistamine 1 to 3 ng twice a week
Number of subjects: 60
Study 16736729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15311117 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m MIBI scintigraphy (30 and 120 minutes)
Number of subjects: 77
Study 15311117 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m MIBI scintigraphy (120 minutes)
Number of subjects: 77
Study 15311117 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m MIBI scintigraphy (30 minutes)
Number of subjects: 77
Study 11314153 — intervention group
Group type: EXPERIMENTAL
Intervention: Entry into randomized controlled trial (RCT)
Number of subjects: 0
Study 11314153 — intervention group
Group type: EXPERIMENTAL
Intervention: Onerous procedures (such as intramuscular injections)
Number of subjects: 0
Study 11314153 — intervention group
Group type: EXPERIMENTAL
Intervention: Best interest deliberation
Number of subjects: 0
Study 9505785 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 72
Study 9505785 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 72
Study 8001531 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink A (90 mmol.l-1 glucose solution)
Number of subjects: 8
Study 8001531 — intervention group
Group type: COMPARATOR
Intervention: Drink B (60 mmol.l-1 sodium chloride)
Number of subjects: 8
Study 8001531 — intervention group
Group type: COMPARATOR
Intervention: Drink C (25 mmol.l-1 potassium chloride)
Number of subjects: 8
Study 8001531 — intervention group
Group type: COMPARATOR
Intervention: Drink D (90 mmol.l-1 glucose, 60 mmol.l-1 sodium chloride and 25 mmol.l-1 potassium chloride)
Number of subjects: 8
Study 3355619 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of encapsulated fish oil per day
Number of subjects: 31
Study 3355619 — intervention group
Group type: COMPARATOR
Intervention: 5 g of encapsulated safflower oil (placebo) per day
Number of subjects: 31
Study 7930868 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 699484 — intervention group
Group type: COMPARATOR
Intervention: Diazepam with water
Number of subjects: 9
Study 699484 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam with magnesium aluminum hydroxide (Maalox)
Number of subjects: 9
Study 699484 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam with aluminum hydroxide trisilicate (Gelusil)
Number of subjects: 9
Study 699484 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam with food
Number of subjects: 9
Study 31851799 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus Bevacizumab
Number of subjects: 806
Study 31851799 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Bevacizumab
Number of subjects: 806
Study 31851799 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus Bevacizumab (HRD-positive tumors with BRCA mutations)
Number of subjects: 806
Study 31851799 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Bevacizumab (HRD-positive tumors with BRCA mutations)
Number of subjects: 806
Study 31851799 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus Bevacizumab (HRD-positive tumors without BRCA mutations)
Number of subjects: 806
Study 31851799 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Bevacizumab (HRD-positive tumors without BRCA mutations)
Number of subjects: 806
Study 28692122 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-18 gene polymorphisms -656 G/T and -607 C/A
Number of subjects: 150
Study 26837842 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 0
Study 26837842 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 0
Study 26837842 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study 26837842 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 0
Study 26837842 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 0
Study 24621390 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlimited access to lactation consultants
Number of subjects: 0
Study 24621390 — intervention group
Group type: COMPARATOR
Intervention: Routine care at the well-baby clinics
Number of subjects: 0
Study 24621390 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants exclusively breastfed for 6 months
Number of subjects: 0
Study 22197578 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9668 60 mg bid
Number of subjects: 615
Study 22197578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 19729935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantharidin blister applied once for 12 hours after a 3-day run-in phase.
Number of subjects: 28
Study 19729935 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list).
Number of subjects: 28
Study 19729935 — intervention group
Group type: COMPARATOR
Intervention: Cantharidin blister vs Control group.
Number of subjects: 28
Study 17597704 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 0
Study 17597704 — intervention group
Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0
Study 12529868 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11197046 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy (30 mg lansoprazole once a day, 400 mg clarithromycin twice a day, 1000 mg amoxicillin twice a day, 300 mg rebamipide three times a day for one week)
Number of subjects: 15
Study 11197046 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (LPZ)
Number of subjects: 15
Study 8837978 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI)
Number of subjects: 21
Study 1430250 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel biofeedback
Number of subjects: 49
Study 1430250 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard biofeedback
Number of subjects: 49
Study 1430250 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study 2864221 — intervention group
Group type: COMPARATOR
Intervention: Beta 2‐agonist therapy alone
Number of subjects: 20
Study 2864221 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 2‐agonist therapy in combination with theophylline
Number of subjects: 20
Study 2864221 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 2‐agonist therapy in combination with enprofylline
Number of subjects: 20
Study 31138577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam (2 g of each per 12 h)
Number of subjects: 154
Study 31138577 — intervention group
Group type: COMPARATOR
Intervention: Cefepime (2 g per 12 h)
Number of subjects: 154
Study 31138577 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone-sulbactam and Cefepime
Number of subjects: 154
Study 27840383 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg/day
Number of subjects: 0
Study 27840383 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg twice daily
Number of subjects: 0
Study 27840383 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg/day (switch from sitagliptin)
Number of subjects: 0
Study 27840383 — intervention group
Group type: COMPARATOR
Intervention: Vildagliptin 50 mg twice daily (switch from sitagliptin)
Number of subjects: 0
Study 27840383 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study 26174133 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg melatonin
Number of subjects: 58
Study 26174133 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 58
Study 26174133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 23965840 — intervention group
Group type: EXPERIMENTAL
Intervention: MedCheck intervention (automated electronic message in a patient Internet portal)
Number of subjects: 738
Study 23965840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MedCheck intervention)
Number of subjects: 738
Study 20926967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest interval of 60 seconds
Number of subjects: 10
Study 20926967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest interval of 90 seconds
Number of subjects: 10
Study 20926967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest interval of 120 seconds
Number of subjects: 10
Study 20926967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest interval of 180 seconds
Number of subjects: 10
Study 20003515 — intervention group
Group type: EXPERIMENTAL
Intervention: Group hearing aid fitting and follow-up visits
Number of subjects: 659
Study 20003515 — intervention group
Group type: COMPARATOR
Intervention: Individual hearing aid fitting and follow-up visits
Number of subjects: 659
Study 20003515 — intervention group
Group type: COMPARATOR
Intervention: Group visits
Number of subjects: 659
Study 20003515 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual visits
Number of subjects: 659
Study 17069923 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment group education
Number of subjects: 101
Study 17069923 — intervention group
Group type: COMPARATOR
Intervention: Routine diabetes care
Number of subjects: 101
Study 15289793 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin for 10 days
Number of subjects: 10
Study 15289793 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rosuvastatin for 10 days
Number of subjects: 10
Study 15289793 — intervention group
Group type: COMPARATOR
Intervention: 10 mg rosuvastatin (historical data)
Number of subjects: 10
Study 11410117 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium (50 mmol/day), low-nitrate (400 micromol/day) diet supplemented with NaCl tablets (200 mmol/day) for 7 days
Number of subjects: 50
Study 9240301 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circuit (n = 15)
Number of subjects: 30
Study 9240301 — intervention group
Group type: COMPARATOR
Intervention: Uncoated extracorporeal circuit (n = 15)
Number of subjects: 30
Study 8317868 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion solution
Number of subjects: 14
Study 3011061 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous No. 00‐plain catgut in the vagina; No. 00‐plain catgut interrupted stitches in the perineal muscles and fascia, and No. 00‐nylon interrupted stitches in the skin.
Number of subjects: 900
Study 3011061 — intervention group
Group type: EXPERIMENTAL
Intervention: No. 0‐polyglycolic acid (Dexon) in all layers.
Number of subjects: 900
Study 3011061 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular technique using No. 0‐polyglycolic acid (Dexon).
Number of subjects: 900
Study 3011061 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified).
Number of subjects: 900
Study 31183945 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (200 mg/day for eGFR ≥60 mL/min/1.73 m² or 100 mg/day for eGFR 41-59 mL/min/1.73 m²)
Number of subjects: 140
Study 31183945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 31183945 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 140
Study 29054128 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination varenicline/bupropion treatment
Number of subjects: 122
Study 29054128 — intervention group
Group type: COMPARATOR
Intervention: Varenicline alone
Number of subjects: 122
Study 26053270 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 30 Units/kg
Number of subjects: 65
Study 26053270 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 60 Units/kg
Number of subjects: 65
Study 26053270 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa (multiple doses)
Number of subjects: 65
Study 23782896 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) with standardized medical treatment if needed
Number of subjects: 400
Study 23782896 — intervention group
Group type: COMPARATOR
Intervention: Standardized medical treatment (control group)
Number of subjects: 400
Study 21694591 — intervention group
Group type: EXPERIMENTAL
Intervention: Female dancers
Number of subjects: 36
Study 21694591 — intervention group
Group type: COMPARATOR
Intervention: Male dancers
Number of subjects: 36
Study 21694591 — intervention group
Group type: COMPARATOR
Intervention: Flat and inclined floors
Number of subjects: 36
Study 19157343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided technique
Number of subjects: 40
Study 19157343 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation guided technique
Number of subjects: 40